The short version of bremelanotide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-18 and is reviewed periodically as new material appears.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
== Stream function for incompressible 2D fluid == Taking the curl of the incompressible Navier–Stokes equation results in the elimination of pressure. This is especially easy to see if 2D Cartesian flow is assumed (like in the degenerate 3D case with
In October 2025, Wander was indicted in the U.S. District Court for the Southern District of New York on federal charges of conspiracy to commit wire fraud, wire fraud, conspiracy to commit securities fraud, and securities fraud. Prosecutors alleged that Wander and his associates defrauded lenders and investors of nearly $500 million through a scheme involving fabricated financial statements, doctored records, and double-pledged collateral. New allegations were made in a superseding indictment on June 30, 2026, further alleging diversion of loan funds, fabrication of financial records, and witness tampering.
== Research == Liposomal medicine research for cancer therapy has increased over the years as an alternative to conventional cancer treatment. There is an interest in liposomal medicine because it features targeted drug delivery while mitigating the damage to healthy cells and tissues. One of the combination products under liposome therapy that is being researched for cancer therapy applications is immunoliposome therapy. Other research areas in liposome combination therapy include photodynamic therapy, photothermal agents, radiotherapy, and gas therapy agents. A immunoliposome therapy clinical study that was completed was conducted by the Swiss Group for Clinical Cancer Research from 2006 to 2009. The study was a phase II clinical trial that looked at the combination of commercially sold Doxorubicin with bevacizumab, a monoclonal antibody that blocks tumor growth. The therapy was used to treat patients with locally recurrent or metastatic breast cancer. Out of the 43 patients, 16 had grade 3 palmar-plantar erythrodysesthesia, one had grade 3 mucositis, and one severe cardiotoxicity, according to the study. As a result, the combination therapy demonstrated higher than anticipated toxicity while only having modest therapeutic effect. These results concluded that, although immunoliposome therapy has promise, there is still more research needed before translating into commercial products.
== As a sweetener == Brazzein represents an alternative to available low-calorie sweeteners. As a protein, it is safe for diabetics. It is also very soluble in water (>50 mg/mL). When blended with other sweeteners, such as aspartame and stevia, brazzein reduces side aftertaste and complements their flavor. Its taste profile is closer to sucrose than other natural sweeteners (apart from thaumatin). Unlike other sweet-tasting proteins, it can withstand heat, making it more suitable for industrial food processing. Papers have been published showing it can be made in a laboratory using peptide synthesis. Recombinant proteins were successfully produced via E. coli. The Texas companies Prodigene and Nectar Worldwide were among the licensees to use Wisconsin Alumni Research Foundation patents on brazzein, and genetically engineer it into maize. Brazzein then can be commercially extracted from the maize through ordinary milling. Approximately one ton of maize yields 1-2 kilograms of brazzein. It can also be engineered into plants like wheat to make pre-sweetened grains, e.g. for cereals. A company was formed to bring it to market as a sweetener in 2008, which initially said it would start selling the product by 2010 once it obtained agreement from the FDA that its brazzein was generally recognized as safe (GRAS). In 2024, the brand Oobli received the first GRAS certification from the FDA, with no potential concerns for consumption being raised.
5-HT1A receptor (as partial or full agonists) 5-HT2A receptor (as inverse agonists) D2 receptor (as antagonists or partial agonists) α1-adrenergic receptor (as antagonists) α2-adrenergic receptor (as antagonists) Actions at D4, 5-HT2C, 5-HT7, and sigma receptors have also been shown for some azapirones. While some of the listed properties such as 5-HT2A and D2 blockade may be useful in certain indications such as in the treatment of schizophrenia (as with perospirone and tiospirone), all of them except 5-HT1A agonism are generally undesirable in anxiolytics and only contribute to side effects. As a result, further development has commenced to bring more selective of anxiolytic agents to the market. An example of this initiative is gepirone, which was recently approved after completing clinical trials in the United States for the treatment of major depression and generalized anxiety disorder. Another example is tandospirone which has been licensed in Japan for the treatment of anxiety and as an augmentation to antidepressants for depression. 5-HT1A receptor partial agonists have demonstrated efficacy against depression in rodent studies and human clinical trials. Unfortunately, however, their efficacy is limited and they are only relatively mild antidepressants. Instead of being used as monotherapy treatments, they are more commonly employed as augmentations to serotonergic antidepressants like the SSRIs.
Sources: en.wikipedia.org
==== ADHD ==== Long-term amphetamine exposure at sufficiently high doses in some animal species is known to produce abnormal dopamine system development or nerve damage, but, in humans with ADHD, long-term use of pharmaceutical amphetamines at therapeutic doses appears to improve brain development and nerve growth. Reviews of magnetic resonance imaging (MRI) studies suggest that long-term treatment with amphetamine decreases abnormalities in brain structure and function found in subjects with ADHD, and improves function in several parts of the brain, such as the right caudate nucleus of the basal ganglia. Reviews of clinical stimulant research have established the safety and effectiveness of long-term continuous amphetamine use for the treatment of ADHD. Randomized controlled trials of continuous stimulant therapy for the treatment of ADHD spanning 2 years have demonstrated treatment effectiveness and safety. Two reviews have indicated that long-term continuous stimulant therapy for ADHD is effective for reducing the core symptoms of ADHD (i.e., hyperactivity, inattention, and impulsivity), enhancing quality of life and academic achievement, and producing improvements in a large number of functional outcomes across 9 categories of outcomes related to academics, antisocial behavior, driving, non-medicinal drug use, obesity, occupation, self-esteem, service use (i.e., academic, occupational, health, financial, and legal services), and social function.
==== National Blue Ribbon Schools of Excellence ==== Beacon Heights Elementary School, Riverdale, 2003–04 Columbia Park Elementary School, Landover, 1987–88 Fort Foote Elementary School, Fort Washington, 2000–01 Glenarden Woods Elementary School, Glenarden, 2005–06 Greenbelt Center Elementary School, Greenbelt, 1991–92 Heather Hills Elementary School, Bowie, 1989–90 Templeton Elementary School, Riverdale, 1998–99 Whitehall Elementary School, Bowie, 2011–12 Kenmoor Middle School, Landover, 1988–89 Dora Kennedy French Immersion, Greenbelt, 2013–14 Kettering Middle School, Upper Marlboro, 1992–93 Martin Luther King, Jr. Middle School, Beltsville, 1992–93 Eleanor Roosevelt High School, Greenbelt, 1990–91 & 1997–98 Suitland High School, Forestville, 1988–89
Westerhoff also notes that for Nāgārjuna, cause and effect do not exist objectively, that is to say, they are not independent of a cognizing subject. As such, cause and effect are "not just mutually interdependent, but also mind-dependent." This means that for Nāgārjuna, causality and causally constructed objects are ultimately just conceptual constructs. Nāgārjuna applies a similar analysis to numerous other kinds of phenomena in the MMK such as motion, the self, and time. Chapter 7 of the MMK attempts to argue against the idea that dependent arising exists either as a conditioned entity or as an unconditioned one. Rejecting both options, Nāgārjuna ends this chapter by stating that dependent arising is like an illusion, a dream or a city of gandharvas (a stock example for a mirage). Chapter 20 tackles the question of whether an assemblage of causes and conditions can produce an effect (it is argued that it cannot). This analysis of dependent arising therefore means that emptiness itself is empty. As Jay Garfield explains, this means that emptiness (and thus dependent origination) "is not a self-existent void standing behind the veil of illusion represented by conventional reality, but merely an aspect of conventional reality."
=== Brand names === As of June 2017, clonidine is marketed under many brand names worldwide: Arkamin, Aruclonin, Atensina, Catapin, Catapres, Catapresan, Catapressan, Chianda, Chlofazoline, Chlophazolin, Clonid-Ophtal, Clonidin, Clonidina, Clonidinã, Clonidine, Clonidine hydrochloride, Clonidinhydrochlorid, Clonidini, Clonidinum, Clonigen, Clonistada, Clonnirit, Clophelinum, Dixarit, Duraclon, Edolglau, Haemiton, Hypodine, Hypolax, Iporel, Isoglaucon, Jenloga, Kapvay, Klofelino, Kochaniin, Lonid, Melzin, Menograine, Normopresan, Paracefan, Pinsanidine, Run Rui, and Winpress. It is marketed as a combination drug with chlortalidone as Arkamin-H, Bemplas, Catapres-DIU, and Clorpres, and in combination with bendroflumethiazide as Pertenso.
=== Prostate cancer === Testosterone promotes growth of many prostate tumors and therefore reducing circulating testosterone to very low (castration) levels is often the treatment goal in the management of men with advanced prostate cancer. GnRH antagonists are used to provide fast suppression of testosterone without the surge in testosterone levels that is seen when treating patients with GnRH agonists. In patients with advanced disease, this surge in testosterone can lead to a flare-up of the tumour, which can precipitate a range of clinical symptoms such as bone pain, urethral obstruction, and spinal cord compression. Drug agencies have issued warnings regarding this phenomenon in the prescribing information for GnRH agonists. As testosterone surge does not occur with GnRH antagonists, there is no need for patients to receive an antiandrogen as flare protection during prostate cancer treatment. GnRH agonists also induce an increase in testosterone levels after each reinjection of the drug – a phenomenon that does not occur with GnRH antagonists. The reduction in testosterone levels that occurs during GnRH antagonist therapy subsequently reduces the size of the prostate cancer. This in turn results in a reduction in prostate-specific antigen (PSA) levels in the patient's blood and so measuring PSA levels is a way to monitor how patients with prostate cancer are responding to treatment.
Sources: en.wikipedia.org
Some have used synteny-based approaches in combination with similarity searches in an attempt to develop standardized, stringent pipelines that can be applied to any group of genomes in an attempt to address discrepancies in the various lists of de novo genes that have been generated.
== Bibliography == Capoccia, Anna Rita (2006). "MAGATI, Cesare". Dizionario Biografico degli Italiani (in Italian). Vol. 67: Macchi–Malaspina. Rome: Istituto dell'Enciclopedia Italiana. ISBN 978-88-12-00032-6. Capparoni, Pietro (1932). "Cesare Magati (Padre Liberato da Scandiano dei Minori Cappuccini)". Profili Bio-bibliografici di Medici e Naturalisti Celebri Italiani Dal Secolo XV al Secolo XVIII. Rome: 70–75. Cesare Magati entry (in Italian) by Agostino Palmerini in the Enciclopedia Treccani, 1934 Putti, Vittorio (1941). "Cesare Magati (1579– 1647)". Biografie di Chirurghi Dal XVI a XIX Secolo. Bologna: 9–16. Premuda, Loris (1970). "Magati, Cesare". In Charles Coulston Gillispie (ed.). Dictionary of Scientific Biography. Vol. 9. New York: Charles Scribner's Sons. pp. 4–5.
Two black spots (ocelli) can be found on each side of the white or orangish nape. The function of these spots is debated, but the most commonly accepted theory is that they act as "false eyes", and help to protect the bird from potential attackers.
== Production == As 225Ac does not occur in any appreciable quantities in nature, it must be synthesized in specialized nuclear reactors or accelerators. The majority of 225Ac results from the alpha decay of 229Th, but this supply is limited because the decay of 229Th (half-life 7920 years) is slow. It is also possible to breed 225Ac from radium-226 in the 226Ra(p,2n) reaction. This was first done in 2005, though the production and handling of 226Ra are difficult because of the respective cost of extraction and hazards of decay products such as radon-222. Alternatively, 225Ac can be produced in spallation reactions on a 232Th target irradiated with high-energy proton beams. Current techniques enable the production of millicurie quantities of 225Ac; however, it must then be separated from other reaction products. This is done by allowing some of the shorter-lived nuclides to decay; actinium isotopes are then chemically purified in hot cells and 225Ac is concentrated. Special care must be taken to avoid contamination with the longer-lived beta-emitting actinium-227. For decades, most 225Ac was produced in one facility—the Oak Ridge National Laboratory in Tennessee—further reducing this isotope's availability even with smaller contributions from other laboratories. Additional 225Ac is now produced from 232Th at Los Alamos National Laboratory and Brookhaven National Laboratory. The TRIUMF facility and Canadian Nuclear Laboratories have formed a strategic partnership around the commercial production of actinium-225.
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
MC4R is regarded as the primary mediator on the basis of binding and functional assays. Other subtypes are also engaged, which helps explain flushing and related side effects. The step from receptor activation to reported desire change remains partly inferential.